


**Amendments to the Claims:**

What is claimed is:

1. (Currently Amended). A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof wherein:

R<sup>1</sup> and R<sup>2</sup>, are, independently selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>3</sup> is selected from the group consisting of phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of F, Cl, trifluoromethyl, naphthyl, and phenyl; naphthyl; and quinolinyl;


R<sup>4</sup> is selected from the group consisting of hydrogen and methyl;

R<sup>5</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl;

R<sup>6</sup> is selected from the group consisting of chlorine, fluorine and hydrogen; and

R<sup>7</sup> and R<sup>8</sup>, are, independently selected from the group consisting of hydrogen, halogen, and C<sub>1</sub>-C<sub>3</sub> alkyl.

2. (Previously Presented). A compound according to claim 1 having formula (II)



(II)

or a pharmaceutically acceptable salt thereof wherein:

R<sup>5</sup> is methyl;

R<sup>6</sup> is hydrogen; and

R<sup>7</sup> and R<sup>8</sup> are each hydrogen.

3. (Previously Presented). A compound or a pharmaceutically acceptable salt thereof, which compound is selected from the group consisting of

*N*-1*H*-Indazol-5-yl-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Biphenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(3,4-Dichlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Fluorophenyl)-*N*-1*H*-indazol-5-yl-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-(3-quinoliny)-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(3-chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-4-(4-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(3-chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

2-Methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Ethyl-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(7-Chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

2-Methyl-*N*-(7-methyl-1*H*-indazol-5-yl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Ethyl-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methyl-*N*-(7-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(7-Chloro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-2-methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(3-ethyl-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-2-methyl-*N*-(7-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(7-chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

2-Methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Ethyl-1*H*-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

2-Methyl-*N*-(7-methyl-1*H*-indazol-5-yl)-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(7-Chloro-1*H*-indazol-5-yl)-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-6-fluoro-1*H*-indazol-5-yl)-4-(4-chloro-2-fluorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-1*H*-Indazol-5-yl-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(3-Hydroxyphenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[4-(Aminosulfonyl)phenyl]-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Cyanophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-1,2-dimethyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoromethyl) phenyl]-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-1,2-dimethyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(3-chloro-1*H*-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-6-fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(trifluoro-methyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-6-fluoro-1*H*-indazol-5-yl)-4-(4-chlorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-2-methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Chloro-1*H*-indazol-5-yl)-4-(4-chlorophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-1*H*-indazol-5-yl-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-*N*-1*H*-indazol-5-yl-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-1*H*-indazol-5-yl-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-1,2-dimethyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-1,2-dimethyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-5-(methyloxy)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-3-(methyloxy)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2-Fluoro-5-hydroxyphenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2-Fluoro-3-hydroxyphenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[5-(Aminosulfonyl)-4-chloro-2-fluorophenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[3-(Aminosulfonyl)-4-chlorophenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[3-(Aminosulfonyl)phenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2,3-Difluorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2,3-Difluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2,4-Difluorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(2,4-Difluorophenyl)-*N*-(1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-(3-hydroxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-4-[3-[(methylsulfonyl)amino]phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-3-nitrophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(3-Amino-4-chlorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-{4-Chloro-3-[(methylsulfonyl)amino]phenyl}-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-4-[3-nitro-4-(trifluoromethyl)phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[3-Amino-4-(trifluoromethyl)phenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-4-[3-[(methylsulfonyl) amino]-4-(trifluoromethyl)phenyl]-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[3-[(Ethylsulfonyl)amino]-4-(trifluoromethyl)phenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-(2-fluoro-5-nitrophenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[4-fluoro-3-(trifluoro methyl)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2,3-Difluoro-4-(trifluoromethyl)phenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[3-fluoro-4-(trifluoromethyl) phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Cyanophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Biphenylyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(2-thienyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Bromophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(5-Cyano-2-fluorophenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-4-[2-fluoro-4-(methyloxy)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-4-[4-chloro-3-(methyloxy)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-4-[4-chloro-3-(methyloxy)phenyl]-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[4-Chloro-3-(methyloxy)phenyl]-2-methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[4-Chloro-3-(methyloxy)phenyl]-*N*-(3-ethyl-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[4-Chloro-3-(methyloxy)phenyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-3-hydroxyphenyl)-*N*-(3-chloro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Bromo-1*H*-indazol-5-yl)-4-(4-chloro-3-hydroxyphenyl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-3-hydroxyphenyl)-2-methyl-*N*-(3-methyl-1*H*-indazol-5-yl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-3-hydroxyphenyl)-*N*-(3-ethyl-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-3-hydroxyphenyl)-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(3-Chloro-1*H*-indazol-5-yl)-4-(4-chlorophenyl)-1,2-dimethyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-1-{[3-(methyloxy)phenyl]methyl}-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

1-Ethyl-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-(6-Fluoro-1*H*-indazol-5-yl)-2-methyl-1-(2-methylpropyl)-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide; and

1-[2-(Dimethylamino)-2-oxoethyl]-*N*-(6-fluoro-1*H*-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide.

4. (Currently Amended). A method of treating ~~disease through inhibiting Rhe-kinases glaucoma~~ comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

5-7. (Canceled).

8. (Currently Amended). A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and a suitable carrier.

9. (Currently Amended) ~~The A compound of Claim 3 or a pharmaceutically acceptable salt thereof, which compound is selected from the group consisting of:~~

*N*-1*H*-Indazol-5-yl-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chloro-2-fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Chlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

*N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(4-Biphenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-(3,4-Dichlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide;

4-[2-Fluoro-4-(trifluoromethyl)phenyl]-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide; and

*N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-(3-quinolinyl)-1,4,5,6-tetrahydro-3-pyridinecarboxamide.

10. (Previously Presented) The compound of Claim 9 which is *N*-1*H*-Indazol-5-yl-2-methyl-4-(2-naphthalenyl)-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) The compound of Claim 9 which is 4-(4-Fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The compound of Claim 9 which is 4-(4-Chloro-2-fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The compound of Claim 9 which is 4-(4-Chlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
14. (Previously Presented) The compound of Claim 9 which is *N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
15. (Previously Presented) The compound of Claim 9 which is 4-(4-Biphenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
16. (Previously Presented) The compound of Claim 9 which is 4-(3,4-Dichlorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
17. (Previously Presented) The compound of Claim 9 which is 4-[2-Fluoro-4-(trifluoromethyl)phenyl]-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
18. (Previously Presented) The compound of Claim 9 which is *N*-1*H*-Indazol-5-yl-2-methyl-6-oxo-4-(3-quinolinyl)-1,4,5,6-tetrahydro-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof.
19. (New) A method of treating glaucoma comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 9 or a pharmaceutically acceptable salt thereof.
20. (New) A pharmaceutical composition comprising a compound according to claim 9 or a pharmaceutically acceptable salt thereof, and a suitable carrier.